In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

China's 3SBio closes $107mm IPO

Executive Summary

Chinese drug developer 3SBio (protein-based therapeutics for nephrology and oncology) completed its initial public offering in the US, netting $107mm through the sale of 7.7mm American Depository Shares at $16 apiece (it had anticipated $12-16); each ADS represents seven ordinary shares.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies